ArticleFrontiers in oncology2026
Female cancers in adolescent and young adult women: global inequities and 2050 burden estimates from GLOBOCAN 2022.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To quantify the global, regional, and national burden of six major female cancers among adolescent and young adult (AYA) women (aged 15-39 years) in 2022, and to project incidence and mortality trends to 2050. Methods: Using GLOBOCAN 2022 estimates, we analyzed incidence, mortality, age-standardized rates, cumulative risk, and mortality-to-incidence ratios (MIRs) for breast, ovarian, corpus uteri, cervical, vaginal, and vulvar cancers across 185 countries. Burden metrics were compared across geographic regions and Human Development Index (HDI) categories. Spearman correlation analyses assessed associations between HDI and cancer burden indicators. Future cancer burden through 2050 was projected based on global demographic forecasts, assuming constant 2022 age-specific incidence and mortality rates. Results: Globally, an estimated 406,385 incident cases and 93,848 deaths from female cancers occurred among AYA women in 2022, corresponding to an ASIR of 24.8 and an ASMR of 5.7 per 100,000 population. Breast cancer accounted for the largest burden of both incident cases and deaths, whereas cervical cancer exhibited the highest mortality-to-incidence ratio, indicating disproportionately poor survival. Considerable geographic and socioeconomic disparities were observed. Very high-HDI countries had the highest incidence but the lowest mortality, whereas low-HDI countries experienced disproportionately high mortality and the highest MIR. HDI was positively associated with incidence (ASIR: ρ = 0.282; cumulative incidence: ρ = 0.302; both Conclusions: Female cancers impose a substantial and inequitable burden among AYA women worldwide. The projected increase in burden, particularly in low-HDI countries, highlights the urgent need to strengthen equitable cancer prevention, early detection, and treatment to reduce global disparities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.